Skip to main content
Top
Published in: memo - Magazine of European Medical Oncology 3/2021

01-09-2021 | short review

Rehabilitation for children and adolescents after cancer: importance and implementation in Austria

Authors: Gustav Fischmeister, David Riedl, Gabriele Sanio, Thomas Bogendorfer, Bernhard Holzner, Gerhard Rumpold, Alain Nickels, Thomas Licht, Wolfgang Sperl

Published in: memo - Magazine of European Medical Oncology | Issue 3/2021

Login to get access

Summary

Until 2018 only adults had access to rehabilitation in Austria, but since then 5 centers for pediatric rehabilitation with different indications have been established with the goal of improving the health of sick children and young adults. The pediatric rehabilitation center “Leuwaldhof”, which is located south of Salzburg, is the only pediatric oncologic rehabilitation center in Austria. It offers rehabilitation and recovery for pediatric patients who suffered from malignancies, as well as for their families and siblings, but also for acute or chronic disease in metabolism or digestion. Cancer and its treatment significantly decrease the quality of life (QoL) of pediatric patients and their families. Families often have to split up during the months of chemotherapy if there are siblings in the family and very often it is the mother who stays with the sick child in the hospital. To facilitate recovery for the families in these difficult times, interdisciplinary and family-oriented inpatient rehabilitation has recently been implemented in Austria. To evaluate the improvements during the rehabilitation, the QoL of the patients and families has been routinely assessed since the opening of the center. In a specifically designed ‘life app’, patients and families complete the Pediatric Quality of Life Inventory (PedsQL; generic score and cancer module) before and after rehabilitation on their own electronic devices. Data of 98 patients and 124 parents between June 2018 and December 2019 show significant improvements in QoL. Our goal is to support the children and their families to help them return to normal life. Our results show rehabilitation helps achieve this important goal.
Literature
6.
go back to reference Sperl W, Nemeth C, Fueloep G, Koller I, Vavrik K, Bernert G, et al. Rehabilitation für Kinder und Jugendliche in Österreich. Stand der Dinge und ein Blick über die Grenzen. Monatsschr Kinderheilkd. 2011;159:618–26.CrossRef Sperl W, Nemeth C, Fueloep G, Koller I, Vavrik K, Bernert G, et al. Rehabilitation für Kinder und Jugendliche in Österreich. Stand der Dinge und ein Blick über die Grenzen. Monatsschr Kinderheilkd. 2011;159:618–26.CrossRef
7.
go back to reference Duffner U, Sauter S, Bergstrasser E, Brandis M, Niemeyer C. Oncologic after-care: a patient-oriented concept. Basic diagnostic plan for pediatric oncology patients. Klin Padiatr. 1995;207:193–203. in German.CrossRef Duffner U, Sauter S, Bergstrasser E, Brandis M, Niemeyer C. Oncologic after-care: a patient-oriented concept. Basic diagnostic plan for pediatric oncology patients. Klin Padiatr. 1995;207:193–203. in German.CrossRef
9.
go back to reference Holzner B, Giesinger JM, Pinggera J, et al. The Computer based Health Evaluation Software (CHES): a software for electronic patient-reported outcome monitoring. BMC Med Inform Decis Mak. 2012;12:126.CrossRef Holzner B, Giesinger JM, Pinggera J, et al. The Computer based Health Evaluation Software (CHES): a software for electronic patient-reported outcome monitoring. BMC Med Inform Decis Mak. 2012;12:126.CrossRef
11.
go back to reference Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQL in pediatric cancer: reliability and validity of the pediatric quality of life inventory generic core scales, multidimensional fatigue scale, and cancer module. Cancer. 2002;94(7):2090–106. https://doi.org/10.1002/cncr.10428. PMID: 11932914.CrossRefPubMed Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQL in pediatric cancer: reliability and validity of the pediatric quality of life inventory generic core scales, multidimensional fatigue scale, and cancer module. Cancer. 2002;94(7):2090–106. https://​doi.​org/​10.​1002/​cncr.​10428. PMID: 11932914.CrossRefPubMed
12.
go back to reference Ellis PD. The essential guide to effect sizes: statistical power, meta-analysis, and the interpretation of research results. Cambridge, New York: Cambridge University Press; 2010.CrossRef Ellis PD. The essential guide to effect sizes: statistical power, meta-analysis, and the interpretation of research results. Cambridge, New York: Cambridge University Press; 2010.CrossRef
16.
go back to reference Eiser C, Varni JW. Health-related quality of life and symptom reporting: similarities and differences between children and their parents. Eur J Pediatr. 2013;172(10):1299–304.CrossRef Eiser C, Varni JW. Health-related quality of life and symptom reporting: similarities and differences between children and their parents. Eur J Pediatr. 2013;172(10):1299–304.CrossRef
17.
go back to reference Ravens-Sieberer U, Karow A, Barthel D, Klasen F. How to assess quality of life in child and adolescent psychiatry. Dialogues Clin Neurosci. 2014;16:147–58.CrossRef Ravens-Sieberer U, Karow A, Barthel D, Klasen F. How to assess quality of life in child and adolescent psychiatry. Dialogues Clin Neurosci. 2014;16:147–58.CrossRef
Metadata
Title
Rehabilitation for children and adolescents after cancer: importance and implementation in Austria
Authors
Gustav Fischmeister
David Riedl
Gabriele Sanio
Thomas Bogendorfer
Bernhard Holzner
Gerhard Rumpold
Alain Nickels
Thomas Licht
Wolfgang Sperl
Publication date
01-09-2021
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2021
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00729-x

Other articles of this Issue 3/2021

memo - Magazine of European Medical Oncology 3/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine